Patterns of care in oligometastatic disease: the clinicians’ perspective

References

• Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–382.
   PubMed Web of Science ®Google Scholar
• Aluwini SS, Mehra N, Lolkema MP, Dutch Oligometastatic Prostate Cancer Working Group, et al. Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting. Eur Urol Oncol. 2020;3(2):231–238.
   PubMed Web of Science ®Google Scholar
• Dagan R, Lo SS, Redmond KJ, et al. A multi-national report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up. Acta Oncol. 2016;55(5):633–637.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Bortolato B, Gerardi MA, Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L), et al. Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiol Med. 2019;124(4):315–322.
   PubMed Web of Science ®Google Scholar
• Lewis SL, Porceddu S, Nakamura N, et al. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol. 2017;40(4):418–422.
   PubMed Web of Science ®Google Scholar
• Mazzola R, Jereczek-Fossa BA, Antognoni P, et al. OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. Med Oncol. 2021;38(5):48.
   PubMed Web of Science ®Google Scholar
• Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3–10.
   PubMed Web of Science ®Google Scholar
• Steenbruggen TG, Schaapveld M, Horlings HM, et al. Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer. JNCI Cancer Spectr. 2021;5:pkab010.
   Web of Science ®Google Scholar
• Levy A, Hendriks LEL, Berghmans T, EORTC Lung Cancer Group (EORTC LCG), et al. EORTC lung cancer group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019;122:109–114.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–166.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28.
   PubMed Web of Science ®Google Scholar
• Sharma A, Minh Duc NT, Luu Lam Thang T, et al. A consensus-based checklist for reporting of survey studies (CROSS). J Gen Intern Med. 2021;36(10):3179–3187.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565.
   PubMed Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051–2058.
   PubMed Web of Science ®Google Scholar
• Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109: djx015.
   Google Scholar
• Lievens Y, Dunscombe P, Defourny N, et al. HERO (Health Economics in Radiation Oncology): a pan-European project on radiotherapy resources and needs. Clin Oncol (R Coll Radiol). 2015;27(2):115–124.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816.
   PubMed Web of Science ®Google Scholar
• Olson R, Mathews L, Liu M, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 2020;20(1):380.
   PubMed Web of Science ®Google Scholar